August 14, 2026 — Leads & Copy — Canopy Growth Corporation announced Friday that its Kincardine, Ontario cultivation facility has successfully renewed its European Union Good Manufacturing Practice (EU GMP) certification. The certification was renewed by the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg.
This renewal allows Canopy Growth to continue supplying Canadian-grown cannabis from its Kincardine facility to medical cannabis markets throughout Europe. The EU GMP status is crucial for exporting medicinal cannabis products to these regions.
Luc Mongeau, Chief Executive Officer of Canopy Growth, stated that the renewal underscores the quality, consistency, and reliability of their cultivation operations at Kincardine. He emphasized the company’s commitment to supplying high-quality EU GMP flower directly from Canada and highlighted plans to expand their flower portfolio with new genetics and strains, including those from MTL Cannabis, to meet the evolving needs of European patients.
The Kincardine facility is a key component of Canopy Growth’s end-to-end EU GMP flower supply chain, linking Canadian-cultivated cannabis to European distribution through the company’s second EU GMP-certified facility located in Sankt Leon-Rot, Germany. The renewed certification coincides with the company’s growing presence in Europe, which contributed to a 10% year-over-year increase in international cannabis net revenue during the first quarter of fiscal year 2027.
Canopy Growth is a global company focused on improving lives through cannabis, with an emphasis on cultivation excellence, quality, trust, innovation, and disciplined execution. The company serves patients, consumers, and partners with a portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL, and R’belle, alongside Storz & Bickel. Canopy Growth also operates as Canada’s leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics. Additionally, the company holds a non-controlling interest in Canopy USA, LLC, providing exposure to the U.S. THC market.
Canopy Growth is dedicated to shaping a future where cannabis is trusted for its ability to enhance lives.
Source: Canopy Growth Corporation
